15 January 2018 - Teva Pharmaceutical Industries announced that the U.S. FDA has approved the use of Trisenox (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukaemia (APL) whose APL is characterised by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. 

The approval was based on a priority review by the FDA on data from published scientific literature and a review of Teva’s global safety database for arsenic trioxide.

Read Teva Pharmaceuticals press release